A Descriptive Pharmaco-epidemiological Study of a Hypertensive Patient Population Treated With a Fixed-dose Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg and of Conditions for the Management of Arterial Hypertension
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,411
- 试验地点
- 915
- 主要终点
- Rate of BP Control in Hypertensive Patients
研究概览
简要总结
It is a national, retrospective , observational study in hypertensive patients treated for at least 8 weeks with the fixed dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg. The primary objective is to assess the control rate (systolic and diastolic blood pressure). Key secondary objectives are to assess the blood pressure reduction after at least 8 weeks of treatment, describe the population treated with this new fixed dose combination
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Rate of BP Control in Hypertensive Patients
时间窗: Baseline to a minimum of 8 weeks of treatment
Percentage of controlled Patients at the Study End. Control rate of hypertension in general practice and in cardiology defined as systolic blood pressure (SBP) and diastolic blood pressure (DBP) \<140/90 mmHg for unselected hypertensive patients and SBP and DBP \<130/80 mmHg for hypertensive patients at high cardiovascular risk (patients with diabetes and patients with impaired renal function) as defined in the recommendations of the French National Health Authority (HAS) 2005 guidelines.
次要结局
- Systolic Blood Pressure (SBP) After at Least 8 Weeks of Treatment in Overall Study Population(baseline to a minimum of 8 weeks of treatment)
- Diastolic Blood Pressure (DBP) After at Least 8 Weeks of Treatment in Overall Study Population(baseline to a minimum of 8 weeks of treatment)
- Systolic Blood Pressure (SBP) After at Least 8 Weeks of Treatment in Population at High Cardiovascular Risk(baseline to a minimum of 8 weeks of treatment)
- Diastolic Blood Pressure (DBP) After at Least 8 Weeks of Treatment in Population at High Cardiovascular Risk(baseline to a minimum of 8 weeks of treatment)
- Rate of BP Control by Risk Factor According to the Recommendations ESH/ESC 2007(Baseline to a minimum of 8 weeks of treatment)